Zyversa Therapeutics Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zyversa Therapeutics Inc 's ROA in the first quarter of 2026?
Zyversa Therapeutics Inc recorded a cumulative net loss of $-24 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -449.92%.

However, within the Healthcare sector 903 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4607, from total ROA ranking in the fourth quarter of 2025 at 5233.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-96.46 %	-98.31 %	-94.64 %	0.88 %	-3.07 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-24	-25	-26	-8	-9
Return On Assets (TTM)	-449.92 %	-237.56 %	-165.07 %	-41.12 %	-43.96 %
ZVSA's Total Ranking	# 4607	# 5233	# 4543	# 3962	# 4070
Total Assets (TTM) in million	1	0	1	20	21
Seq. Total Assets Change	113.35 %	-66.56 %	-94.7 %	-6.41 %	1.87 %
Seq. Net Income Change	-	-	-	-	-

ZVSA's 5 Years Annual ROA >> Back to ZVSA Management Effectiveness >> Compare ZVSA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 432
Sector	# 904
Overall	# 4556

Return On Assets Statistics
High	Average	Low
-41.12 %	-173.23 %	-449.92 %
(Jun 30 2025)		(Mar 31 2026)

Financial Statements
Zyversa Therapeutics Inc 's Assets	$ 1 million	ZVSA's Balance sheet
Zyversa Therapeutics Inc 's Income	$ -2 million	Quarterly ZVSA's Income Statement
ZVSA's Income by Division		See ZVSA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2021) FY 2021	FY
Y / Y Total Assets Change	-98.31 %	-6.85 %	-83.32 %	71.85 %	-
Total Assets in million	0	21	22	133	77
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-25	-9	-14	0	0
Annual Return On Assets	-7172.24 %	-45.7 %	-63.52 %	-0.18 %	-

ZVSA's 5 Years Annual ROA >> Back to ZVSA Management Effectiveness >> Compare ZVSA ROA to its Competitors

More Return On Assets Ratios
ZVSA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZVSA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZVSA's Competitors
Subscribers only: Roa for Zyversa Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ZVSA's Customers

You may also want to know
ZVSA's Roi	ZVSA's Inventory Turnover Ratio	ZVSA's Growth Rates	ZVSA's Dividend Comparisons
	ZVSA's Profitability Ratios	ZVSA's Asset Turnover Ratio	ZVSA's Dividend Growth
ZVSA's Roe	ZVSA's Valuation Ratios	ZVSA's Financial Strength Ratios	ZVSA's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.